Durability of Lamivudine associated HBe antigen seroconversion in Chinese-Canadian patients with chronic hepatitis B virus infection
✍ Scribed by Ramji, Alnoor S.; Yoshida, Eric M.; Kwan, Peter W.
- Book ID
- 123155645
- Publisher
- Elsevier Science
- Year
- 2003
- Tongue
- English
- Weight
- 217 KB
- Volume
- 124
- Category
- Article
- ISSN
- 0016-5085
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ؍ 60
A commercial radioimmunoassay was adapted to detect serum Dane particle-associated HBeAg in patients whose sera contained the homologous antibody. HBeAg was released from Dane particles with guanidine HC1. Dane particles were separated from anti-HBe by gel-filtration (Sepharose 4B) and ultracentrif